MEMPHASYS LIMITED(MEM)

The suspension of trading in the securities of Memphasys Limited will be lifted immediately following the release by MEM of an announcement regarding a capital raising.

The company plans to raise A$1.0 million through a placement, supported by existing shareholders and new investors. Memphasys will offer shareholders access to the same terms via a Share Purchase Plan. Eligible shareholders can raise up to A$1.0 million. Proceeds will be used for the finalization of the FelixTM clinical trial, an equine fertility study, and a study on oxidative stress.

The securities of Memphasys Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MEM, pending the release of an announcement regarding a capital raising.

The suspension of trading in the securities of Memphasys Limited will be lifted immediately following the release by MEM of an announcement regarding a capital raising.

Placement to raise approximately $1.6M at 2 cents per share. Fully underwritten, non-renounceable entitlement offer to raise up to $1.76M (1 new share for every 9 held on the record date at 2 cents per share). Funds will be used predominantly to continue commercialisation of the Felix System, undertake Felix System clinical trials and other regulatory activities, and to continue the development of other pipeline products with the University of Newcastle research team.

On 10 August 2022, the Supreme Court of Western Australia heard the company's application seeking orders in relation to four inadvertent administrative errors whereby the Company failed to lodge a cleansing notice. The Court has granted orders validating any subsequent offer for sale or sale of the Uncleansed Shares. The company is now able to shift itsfocusto completion of its proposed capital raising, which shall comprise a placement and pro-rata entitlement offer. The comapny will remain in voluntary suspension to facilitate an orderly market in its securities pending release of an announcement with respect to the capital raising, which is anticipated to be on or around Monday, 15 August 2022.

The company releases a cleansing statement in relation to the issue of 1,333,334 Shares, which was completed on 21 October 2019.

The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report.

The securities of Memphasys Limited ("˜MEM') will be suspended from quotation immediately under Listing Rule 17.2, at the request of MEM, pending the release of an announcement regarding a court application concerning the failure to lodge cleansing notices in connection with the issue of shares on 3 September 2015, 30 May 2017, 21 October 2019 and 17 July 2020.

we understand that on or about this date the company consolidated its shares 1 for 15

name changed from Nusep Holdings Ltd